Michael John Sumner - 04 Mar 2026 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Reporting relationship: Chief Medical Officer
Issuer ticker: INO
Reported as of: 04 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2026, 16:54:42 UTC
Prior SEC filing: 27 Feb 2026
Next SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael John Sumner

Key filing fact

Michael John Sumner filed Form 4 for INOVIO PHARMACEUTICALS, INC. (INO) on 05 Mar 2026.

Key facts

This page summarizes Michael John Sumner's Form 4 filing for INOVIO PHARMACEUTICALS, INC. (INO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Mar 2026, 16:54.

Change

Previous filing in this sequence was filed on 27 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001936799 Primary reporting owner

Sumner Michael John

Relationship: Chief Medical Officer
Address: 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING
Signature: /s/ Michael John Sumner
Signature date: 05 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INO transaction Derivative

Common Stock Option

Award

Transaction value
Shares: +36,832
Change %
Price: $0.000000^*
Shares after: 36,832
Date: 04 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 36,832
Exercise price: $1.73
Footnotes: F1

INO transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +29,608
Change %
Price: $0.000000^*
Shares after: 29,608
Date: 04 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,608
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The vesting schedule for the 36,832 options granted on March 4, 2026 was as follows: 12,278 shares will vest on February 26, 2027; 12,277 shares will vest on February 26, 2028; 12,277 shares will vest on February 26, 2029.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 29,608 restricted stock units granted on March 4, 2026 was as follows: 9,870 shares will vest on February 26, 2027; 9,869 shares will vest on February 26, 2028; and 9,869 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.